CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: HARRY GIBSON who started this subject	10/3/2000 6:40:10 AM
From: nigel bates	Read Replies (1) of 666

LONDON, Oct 3 (Reuters) - Biotechnology firm ML Laboratories Plc (LSE: MLB.L - news) said on Tuesday its gene therapy unit Cobra Therapeutics had agreed to develop and commercialise some of Cobra's novel UCOE applications with U.S. Coulter Pharmaceutical Inc . UCOE, ubiquitous chromatin opening elements, is a technology with a wide range of applications in biotechnology and drug discovery including rapid production of proteins such as antibodies. "The application of our technology in this area is particularly important as it represents a major class of therapeutic proteins and consequently offers significantly commercial potential," said ML chief executive Stuart Sim in a statement...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next